Executive Vice President
Mapi Pharma
uri@mapi-pharma.com

Uri Danon serves as Executive Vice President at Mapi Pharma, that develops extended-release versions of existing commercially successful products that target large markets, as well as high-barrier to entry and high-added value generic drugs. He served as President and CEO of BioCancell Therapeutics Inc. (TASE: BICL), a clinical stage anti-cancer drug development company. Previous to that, he served as CEO and later Chairman of Atox Bio Ltd., that develops therapeutics for severe infections, now in phase III. Prior to that, he served as CEO of Epigenesis, Ltd., a cell therapy development company. Previous to that, he managed international projects for Teva Pharmaceutical Industries Ltd., including the development of Copaxone in solution in pre-filled syringes (sales, $4.3 billion / year). Uri Danon has business, operational, R&D and management experience, as well as licensing of stem cell, cell therapy, biologics and pharmaceutical products.
Mr. Danon holds an MBA in marketing from Bar Ilan University, Israel, and a B.Sc. in industrial engineering and management from Tel Aviv University, Israel.